Abstract 2670
Background
Clinical and molecular heterogeneity of GC is broadly recognized. Three molecular classifications based on sample profiling from resected early-stage tumours have been proposed. Apart from microsatellite instability (MSI) subgroup, they provide conflicting results and are difficult to implement in the met population. We aimed to develop and adapt a molecular classification for stratifying met patients(pt).
Methods
Fifty surgical samples from GC pt (Dec 2006 – Jan 2017) who relapsed were selected. We performed 1) exon-capture next generation sequencing for mutation(mut) (430 genes, including TP53, PIK3CA, CDH1, RHOA, BRCA1/2, ATM); 2) immunohistochemistry of HER2, MET, MLH1, MSH2, MSH6, PMS2, CDH1, MUC6, MUC5AC, PDL1; and 3) in situ hybridization of HER2, EBV, FGFR2, MET. Tumour mut burden (TMB) defined as number of non-synonymous mut per megabase (Mb) of coding region. Grant PI17/00117.
Results
Forty-nine pt had evaluable molecular data, 26 (53%) diffuse subtype, 11 (22%) intestinal, 12 (24%) mixed. Eight tumours were HER2-positive (-pos) (16%), 3 MSI-pos (6%), and 2 EBV-pos (4%). Gene mut and copy number variations (CNVs) involving receptor kinases, cell cycle, epigenetic and DNA damage repair pathways were detected in more than 50%. TP53 mut were found in 21 (43%), whereas CDH1 in 10 (20%), ARID1A in 9 (18%), and LRP1B in 8 (16%). Diffuse subtype had an enrichment for CDH1 mut (31%), and intestinal for TP53 mut (82%). We found no enrichment for CNVs in histopathology subtypes, but 6 out of 8 HER2 amplified cases were TP53 mut intestinal. TP53 wild type (wt) tumours had higher expression of MUC6, MUC5A and lower PDL1 combined score (p < 0.05). Outlier high PDL1 expression and high TMB (> 10 mut/Mb) were not limited to MSI and EBV-pos. TMB was higher in samples with alterations in DNA damage repair genes (median 6 mut/Mb) or TP53 mut (median 5.4 mut/Mb) as compared to wt (median 3.1 mut/Mb, p < 0.05). The overall survival in the met setting was longer in pt with DNA damage repair mut (36.7m) than wt (11.5m; HR 0.51; p = 0.06). All pt had received a platinum-based chemo, none immunotherapy.
Conclusions
The molecular landscape of met GC is unique and may guide development of matched therapies. Our findings will be validated in a larger cohort of 135 samples.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Vall d’Hebron Institute of Oncology (VHIO).
Funding
Instituto Carlos III - Proyectos de Investigación en Salud PI17/00117.
Disclosure
M. Alsina Maqueda: Research grant / Funding (institution), Travel / Accommodation / Expenses: Merck; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses, Honoraria for speaking issues: Servier; Honoraria (self), Advisory / Consultancy, Honoraria for speaking issues: BMS; Honoraria (self), Advisory / Consultancy, Honoraria for speaking issues: MSD; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses, Honoraria for speaking issues: Lilly; Honoraria (self), Travel / Accommodation / Expenses, Honoraria for speaking issues: Roche; Honoraria (self), Travel / Accommodation / Expenses, Honoraria for speaking issues: Amgen. M. Diez: Travel / Accommodation / Expenses: Ipsen; Travel / Accommodation / Expenses: Lilly; Travel / Accommodation / Expenses: Servier. J. Tabernero: Advisory / Consultancy: Array Biopharma; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Bayer; Advisory / Consultancy: BeiGene; Advisory / Consultancy: Boehringer Ingelheim; Advisory / Consultancy: Chugai; Advisory / Consultancy: Genentech; Advisory / Consultancy: Genmab A/S; Advisory / Consultancy: Halozyme; Advisory / Consultancy: Imugene Limited; Advisory / Consultancy: Inflection Biosciences Limited; Advisory / Consultancy: Ipsen; Advisory / Consultancy: Kura Oncology; Advisory / Consultancy: Lilly; Advisory / Consultancy: MSD; Advisory / Consultancy: Menarini; Advisory / Consultancy: Merck Serono; Advisory / Consultancy: Merrimack; Advisory / Consultancy: Merus; Advisory / Consultancy: Molecular Partners. P.G. Nuciforo: Advisory / Consultancy: Bayer; Advisory / Consultancy: Novartis; Advisory / Consultancy: MSD. A. Vivancos: Advisory / Consultancy, Research grant / Funding (institution): Sysmex; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy: Merck; Advisory / Consultancy, Research grant / Funding (institution): Roche; Advisory / Consultancy, Research grant / Funding (institution): BMS; Advisory / Consultancy: Guardant Health; Licensing / Royalties, Technology Transfer DX Field: Ferrer; Research grant / Funding (institution): Debio; Research grant / Funding (institution): Cellestia Biothech; Research grant / Funding (institution): Chittern. R. Dienstmann: Advisory / Consultancy, Honoraria for speaking: Roche; Honoraria (self), Honoraria for speaking: Symphogen; Honoraria (self), Honoraria for speaking: Ipsen; Honoraria (self), Honoraria for speaking: Amgen; Honoraria (self), Honoraria for speaking: Sanofi; Honoraria (self), Honoraria for speaking: MSD; Honoraria (self), Honoraria for speaking: Servier; Research grant / Funding (self): Merck. All other authors have declared no conflicts of interest.
Resources from the same session
3911 - Defining a SUV decrease cut-off in PET/CT response monitoring after one cycle of preoperative breast cancer chemotherapy
Presenter: Marcin Kubeczko
Session: Poster Display session 2
Resources:
Abstract
1849 - Effect of thioredoxin 1 quantity detection to complement the mammography in breast cancer diagnosis
Presenter: Younju Lee
Session: Poster Display session 2
Resources:
Abstract
2221 - Identification of ultralow risk breast cancer patients (probable overdiagnosis)
Presenter: Salvador Gamez Casado
Session: Poster Display session 2
Resources:
Abstract
5291 - Prevalence of Vitamin D3 deficiency among women with early breast cancer receiving chemotherapy in an oncology dayward.
Presenter: Warner Finstad
Session: Poster Display session 2
Resources:
Abstract
4247 - Changes in ER pathway activity score during neoadjuvant letrozole to assess therapy response and predict disease free survival (DFS) in ER positive breast cancer patients
Presenter: Arran Turnbull
Session: Poster Display session 2
Resources:
Abstract
568 - Second primary malignancies in patients with breast cancer.
Presenter: Carlos Erasun Lecuona
Session: Poster Display session 2
Resources:
Abstract
1428 - Phase II randomized trial of neoadjuvant trastuzumab and pertuzumab (TP) with either palbociclib + letrozole (Pal+L) or paclitaxel (Pac) for elderly patients with estrogen receptor & HER2 positive (ER+/HER2+) Breast Cancer (BC) (International Breast Cancer Study Group IBCSG 55-17, TOUCH)
Presenter: Laura Biganzoli
Session: Poster Display session 2
Resources:
Abstract
1479 - Neoadjuvant HER2-targeted therapy with or without immunotherapy with pembrolizumab (neoHIP): an open label randomized phase 2 trial
Presenter: Heather McArthur
Session: Poster Display session 2
Resources:
Abstract
1481 - A randomized phase 2 study of peri-operative ipilimumab, nivolumab and cryoablation versus standard care in women with residual, early stage/resectable, triple negative breast cancer after standard-of-care neoadjuvant chemotherapy
Presenter: Heather McArthur
Session: Poster Display session 2
Resources:
Abstract
4334 - ALEXANDRA/IMpassion030: A phase 3 study of standard adjuvant chemotherapy with or without atezolizumab in early stage triple negative breast cancer.
Presenter: Michail Ignatiadis
Session: Poster Display session 2
Resources:
Abstract